search
Back to results

Prognostic Value of Functional Exercise Test (EFX) in Cystic Fibrosis (EFX)

Primary Purpose

Cystic Fibrosis

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
cardiopulmonary exercise testing
Sponsored by
University Hospital, Lille
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Cystic Fibrosis focused on measuring cystic fibrosis, Cardiopulmonary exercise testing, prognostic

Eligibility Criteria

15 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age more than 15 years
  • Cystic fibrosis diagnosed by positive sweat chloride test or genetic test

Exclusion Criteria:

  • Pregnant or breastfeeding woman
  • waiting on transplantation list

Sites / Locations

  • Hôpital Calmette, CHRU

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

cystic fibrosis patients

Arm Description

Outcomes

Primary Outcome Measures

Survival
the survival is defined by the occurrence of death or lung transplantation.

Secondary Outcome Measures

6 minute walking distance
body mass index calculation
sputum sample culture
(a descriptive analysis of Haemophilus influenzae, Staphylococcus aureus, Pseudomonas aeruginosa,Burkholderia cepacia streptococci in the bacterial flora of sputum)
pulmonary function testing with DLCO
diffusing lung capacity for carbon monoxide.

Full Information

First Posted
August 16, 2016
Last Updated
February 3, 2023
Sponsor
University Hospital, Lille
search

1. Study Identification

Unique Protocol Identification Number
NCT02994017
Brief Title
Prognostic Value of Functional Exercise Test (EFX) in Cystic Fibrosis
Acronym
EFX
Official Title
Prognostic Value of Functional Exercise Test (EFX) in Cystic Fibrosis
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Completed
Study Start Date
March 5, 2012 (Actual)
Primary Completion Date
June 16, 2019 (Actual)
Study Completion Date
June 16, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Lille

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The objective of study is to prospectively determine if CPET with blood gas analysis should have a prognostic value in CF. The study plans to include 300 cystic fibrosis patients. Inclusion criteria will be: age >15 years, cystic fibrosis confirmed by chloride sweat test or genetic analysis, clinical and functional stability in the 2 month before CPET. Patients will perform a maximal exercise test on a cycloergometer during the inclusion visit, with pulmonary function testing and a six-minute walk test. The study will also include a visit every 6 months with: body mass index calculation, pulmonary function testing with DLCO (diffusing lung capacity for carbon monoxide), a six minute walk test, and antibacteriological study of sputum. The results of this study could help identify earlier the patients for referral to a lung transplantation centre, by using the usual criteria and the CPET abnormalities.
Detailed Description
Current guidelines for referring cystic fibrosis (CF) patients for lung transplantation, based on clinical and functional resting parameters, are insufficient to predict 3-year mortality. Previous studies have shown that sex, impaired pulmonary function, undernutrition and colonization of the respiratory tract by Pseudomonas aeruginosa are associated with a poor prognosis. Current guidelines for referral to a lung transplant center include age, sex, forced expiratory volume at one second (FEV1) below 30% predicted or a rapid decline of FEV1, in particular in young female patients, increasing frequency of exacerbations requiring antibiotic therapy, refractory or recurrent pneumothorax, recurrent hemoptysis not controlled by embolization. But, despite these criteria, near that 30% of patients are still dying while on the lung transplant waiting list, or are transplanted in high emergency. Cardiopulmonary exercise testing (CPET) in CF patients would have an interest in the following of cystic fibrosis patients. A previous study, carried out on fifty one adult patients, showed that CPET with blood gas analysis may have a prognosis value in cystic fibrosis. The authors found that a BMI < 19.8 and P(A-a)O2 peak > 43 mmHg were independently associated with a lower chance of survival.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cystic Fibrosis
Keywords
cystic fibrosis, Cardiopulmonary exercise testing, prognostic

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
287 (Actual)

8. Arms, Groups, and Interventions

Arm Title
cystic fibrosis patients
Arm Type
Other
Intervention Type
Other
Intervention Name(s)
cardiopulmonary exercise testing
Intervention Description
The Cardiopulmonary exercise testing (CPET) was performed at the beginning of the study, the same at each center. Each patient underwent a symptom-limited incremental exercise test on an ergometric bicycle (Ergoline-Ergometrics 800®). The protocol included a warm-up period of 3 min at 20 W followed by a progressively increasing work rate (WR) in a ramp fashion and then 3 min recovery. The ramped WR increment was individualized (range,8-30 W/min). during exercise, heart rate (HR) was monitored continuously by 12-lead ECG, and arterial oxygen saturation (SpO2) was measured by pulse oximetry (Nellcor N-395). The expired gases were analyzed with an Ergocard®, focusing on oxygen consumption(VO2), carbon dioxide production (VCO2), minute ventilation (VE), and tidal volume (VT).
Primary Outcome Measure Information:
Title
Survival
Description
the survival is defined by the occurrence of death or lung transplantation.
Time Frame
at five years
Secondary Outcome Measure Information:
Title
6 minute walking distance
Time Frame
Every 12 months during 5 years
Title
body mass index calculation
Time Frame
Every 12 months during 5 years
Title
sputum sample culture
Description
(a descriptive analysis of Haemophilus influenzae, Staphylococcus aureus, Pseudomonas aeruginosa,Burkholderia cepacia streptococci in the bacterial flora of sputum)
Time Frame
Every 12 months during 5 years
Title
pulmonary function testing with DLCO
Description
diffusing lung capacity for carbon monoxide.
Time Frame
Every 12 months during 5 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
15 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age more than 15 years Cystic fibrosis diagnosed by positive sweat chloride test or genetic test Exclusion Criteria: Pregnant or breastfeeding woman waiting on transplantation list
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anne Prevotat, MD
Organizational Affiliation
University Hospital, Lille
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hôpital Calmette, CHRU
City
Lille
Country
France

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Prognostic Value of Functional Exercise Test (EFX) in Cystic Fibrosis

We'll reach out to this number within 24 hrs